Company Analysis

Liminatus Pharma, Inc. (LIMN)

Nasdaq: LIMN · Biological Products, (No Diagnostic Substances) · Cerritos, CA · filing with the SEC since 2023
Grade4.1
◀ Past 3.5● Present 3.4▶ Future 5.0
7 est.

Who runs Liminatus Pharma, Inc.

Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filed
Chief executive, as filed
Kim Chris
Chief Executive Officer. First filing Apr 2025, latest Jul 14, 2026, 0 filings in all.
Officers reporting now
1
of 3 people with a filing in the last fifteen months
Directors reporting now
2
10 people on the record since 2025
Officerssales are open-market, Sep 30, 2025 to Sep 30, 2026
NameTitle as filedFirst filingLatest filingSales, 12 months
Kim ChrisChief Executive OfficerApr 2025Jul 14, 2026none
Directorssales are open-market, Sep 30, 2025 to Sep 30, 2026
NameRoleFirst filingLatest filingSales, 12 months
Lemons II Philip WaynedirectorJul 2025Jul 23, 2025none
Baek Richard JaihwandirectorJul 2025Jul 21, 2025none
Owners of more than 10% of a classsales are open-market, Sep 30, 2025 to Sep 30, 2026
NameRoleFirst filingLatest filingSales, 12 months
Valetudo Therapeutics LLC10% ownerJun 2025Jul 14, 2026none
Ewon Comfortech Co., Ltd.10% ownerJul 2026Jul 6, 2026none
Iris Acquisition Holdings LLC10% ownerAug 2025Aug 15, 2025none
Earlier names on the record8, newest filing first

A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.

SI Assistanton LIMN · research, not advice